Oramed Pharmaceuticals is UNDERVALUED at 16.33 per share with modest projections ahead.
Oramed Pharmaceuticals appears to be somewhat reliable, given 3 months investment horizon.
Oramed Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of 0.18, which implies the firm had 0.18% of return per unit of risk over the last 3 months. Our standpoint towards forecasting the volatility of a stock is to use all available market data together with stock-specific
technical indicators that cannot be
diversified away. By analyzing
Oramed Pharmaceuticals technical indicators you can presently evaluate if the expected return of 0.89% is justified by implied risk. Please evaluate Oramed Pharmaceuticals' Coefficient Of Variation of 609.36,
semi deviation of 3.45, and Risk Adjusted Performance of 0.2248 to confirm if our risk estimates are consistent with your expectations.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Oramed Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Potential Oramed Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Oramed Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Oramed Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Oramed Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Oramed Pharmaceuticals
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Oramed Pharmaceuticals performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Oramed Pharmaceuticals shares is the value that is considered the true value of the share. If
the intrinsic value of Oramed is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Oramed Pharmaceuticals. Please read more on our
fundamental analysis page.
How effective is Oramed Pharmaceuticals in utilizing its assets?
Oramed Pharmaceuticals reports assets on its Balance Sheet. It represents the amount of Oramed resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Oramed Pharmaceuticals aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Pharmaceuticals space. To get a better handle on how balance sheet or income statements item affect Oramed volatility, please check the breakdown of all its
fundamentals.
Are Oramed Pharmaceuticals Earnings Expected to grow?
The
future earnings power of Oramed Pharmaceuticals involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Oramed Pharmaceuticals factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Oramed Pharmaceuticals
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Oramed
expected earnings.
Oramed Pharmaceuticals Gross Profit
Oramed Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Oramed Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Oramed Pharmaceuticals Gross Profit growth over the last 10 years. Please check Oramed Pharmaceuticals'
gross profit and other
fundamental indicators for more details.
Breaking it down
The company reported the previous year's revenue of 2.7
M. Net Loss for the year was (22.24
M) with profit before overhead, payroll, taxes, and interest of 2.71
M.
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Oramed Pharmaceuticals has an asset utilization ratio of 63376.32 percent. This suggests that the company is making $633.76 for each dollar of assets. An increasing asset utilization means that Oramed Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 159.62 Million | 99.02 |
| Assets Non Current | 1.58 Million | 0.98 |
Momentum Analysis of Oramed Pharmaceuticals suggests possible reversal in January
Recent value at risk indicator falls down to -5.23. Possible price boost?
As of the 27th of December, Oramed Pharmaceuticals holds the Semi Deviation of 3.45,
risk adjusted performance of 0.2248, and Coefficient Of Variation of 609.36. Compared to
fundamental indicators, the
technical analysis model allows you to check existing technical drivers of Oramed Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We have collected data for nineteen
technical drivers for Oramed Pharmaceuticals, which can be compared to its competitors. Please check
Oramed Pharmaceuticals standard deviation, as well as the
relationship between the maximum drawdown and
expected short fall to decide if Oramed Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 10.95 per share. Given that Oramed Pharmaceuticals has
jensen alpha of 0.5932, we recommend you to check out Oramed Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.
The Current Takeaway on Oramed Pharmaceuticals Investment
Although other companies under the biotechnology industry are still a bit expensive, Oramed Pharmaceuticals may offer a potential longer-term growth to insiders. To sum up, as of the 27th of December 2022, we believe that Oramed Pharmaceuticals is currently
undervalued with
below average odds of financial distress in the next two years. Our primary 90 days advice on the firm is
Strong Buy.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Oramed Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com